<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292226</url>
  </required_header>
  <id_info>
    <org_study_id>ML19835</org_study_id>
    <nct_id>NCT01292226</nct_id>
  </id_info>
  <brief_title>A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).</brief_title>
  <official_title>Relationships Between Pharmacokinetic and Pharmacodynamic Strategies for Assessment of the Risks for Acute Rejection and Side Effects of Mycophenolate Mofetil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will evaluate the correlation between the pharmacokinetic and pharmacodynamic
      parameters of CellCept in patients undergoing primary kidney transplantation, in order to
      assess the impact on clinical outcome and the risks of acute rejection. All patients will
      receive oral CellCept, 1g twice daily, and pharmacokinetic and pharmacodynamic parameters
      will be measured at weeks 2, 4, 12 and 24. The anticipated time on study treatment is 24
      weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Acute Rejection</measure>
    <time_frame>Day 1, Weeks 2, 4, 12, 24, and 28</time_frame>
    <description>Diagnosis of acute rejection was suspected in any participant with an increase in serum creatinine greater than or equal to (â‰¥) 25 percent (%). All suspected acute rejections were confirmed by biopsy. The start date of acute rejection was identified as the date of biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Rejection</measure>
    <time_frame>Day 1, Weeks 2, 4, 12, 24, and 28</time_frame>
    <description>The mean time, in days, from the date of enrollment to date of biopsy confirming acute rejection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR)</measure>
    <time_frame>Day 1, Weeks 2, 4, 12, 24, and 28</time_frame>
    <description>BPAR was defined according to 1997 Banff Criteria as a biopsy Banff grade of IA, IB, IIA, IIB, or III. Grade IA was defined as significant interstitial infiltration with greater than (&gt;)25% of parenchyma affected, and foci of moderate tubulitis with &gt;4 mononuclear cells per tubular cross section or group of 10 tubular cells. Grade IB was defined as significant interstitial infiltration with &gt;25% parenchyma affected, and foci of severe tubulitis with &gt;10% mononuclear cells per tubular cross section or group of 10 tubular cells. Grade IIA was defined as mild to moderate intimal arteritis. Grade IIB was defined as severe intimal arteritis comprising &gt;25% of the luminal area. Grade III was defined as transmural arteritis and/or arterial fibrinoid changes and necrosis of medial smooth muscle cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Graft Loss</measure>
    <time_frame>Day 1, Weeks 2, 4, 12, 24, and 28</time_frame>
    <description>An allograft was presumed to be lost if a participant started dialysis and was not able to subsequently be removed from dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Surviving</measure>
    <time_frame>Day 1, Weeks 2, 4, 12, 24, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Mycophenolate Acid (MPA) by Visit and Timepoint</measure>
    <time_frame>Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up Visit), and any unscheduled visits</time_frame>
    <description>Drug quantification of total MPA (micrograms per milliliter [mcg/mL]) in the plasma was measured at time (T) = 0 minutes (min), 40 mins, and 120 mins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free MPA (mcg/mL) by Visit</measure>
    <time_frame>Weeks 2, 4, 12, 24, safety follow-up (Week 28), and any unscheduled visits</time_frame>
    <description>Drug quantification of free MPA in the plasma was measured at T = 0, 40, and 120 mins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPA Area Under the Concentration - Time Curve From Time 0 to 12 Hours (AUC0-12) (mcg/mL) by Visit</measure>
    <time_frame>Predose and 40 minutes and 2 hours postdose at Weeks 2, 4, 12, and 24, and at the Safety follow-up (Week 28)</time_frame>
    <description>The AUC0-12 of MPA was estimated on the validated limited sampling strategy, AUC (milligrams multiplied by height over liter [mg.h/L]) = 7.182 + 4.607 multiplied by (*) concentration at 0 minutes (C0)+ 0.998 * the concentration at 40 minutes (C0.67) + 2.149 * the concentration at 120 minutes (C2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inosine MonoPhosphate DeHydrogenase (IMPDH) Activity by Visit and Timepoint</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits</time_frame>
    <description>IMPDH activity in peripheral blood mononuclear cells (PBMCs) was measured at 2 timepoints per visit, 0 and 120 minutes and presented in enzyme units. The unit of measure of enzyme activity is &quot;U&quot;. One U is defined as the amount of the enzyme that produces a certain amount of enzymatic activity that is, the amount that catalyzes the conversion of 1 micro mole of substrate per minute under pre-specified conditions (temperature, pH).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IMPDH Expression I by Visit and Timepoint</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits</time_frame>
    <description>IMPDH I gene expression was measured by real time polymerase chain reaction (QRT-PCR) based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of messenger ribonucleic acid (mRNA) copies per cell (copies/cell).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IMPDH Expression II by Visit and Timepoint</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits</time_frame>
    <description>IMPDH II gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 8 (IL-8) Expression by Visit and Timepoint</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits</time_frame>
    <description>IL-8 gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Necrosis Factor (TNF) Expression by Visit and Timepoint</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits</time_frame>
    <description>TNF gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Infection</measure>
    <time_frame>BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)</time_frame>
    <description>Infections were graded according to the World Health Organization (WHO) worst grade observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Gastrointestinal Toxicities</measure>
    <time_frame>BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-up Visit)</time_frame>
    <description>Gastrointestinal adverse events (AEs) according to WHO worst grade observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hematologic Toxicity</measure>
    <time_frame>BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)</time_frame>
    <description>Hematological toxicities graded according to WHO worst grade observed (Grade 1=mild, Grade 2=moderate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spearman's Rank Correlation Coefficient Between MPA Levels and IMPDH Activity</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
    <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spearman's Rank Correlation Coefficient Between IMPDH I Expression and MPA Levels</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
    <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spearman's Rank Correlation Coefficient Between IMPDH I Expression and Free Fraction</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
    <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spearman's Rank Correlation Coefficient Between IMPDH II Expression and MPA Levels</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
    <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spearman's Rank Correlation Coefficient Between IMPDH II Expression and Free Fraction</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
    <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spearman's Rank Correlation Coefficient Between IMPDH Inhibition and Risk of Acute Rejection</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
    <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Infection</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
    <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Hematologic Toxicity</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
    <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Gastrointestinal Toxicity</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
    <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Infection</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
    <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Hematologic Toxicity</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
    <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Gastrointestinal Toxicity</measure>
    <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
    <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an initial dose of mycophenolate mofetil (MMF), 1 gram (g), orally (PO), twice per day (BID), within 5 days of transplant for 24 weeks. Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>1 g PO BID for 24 weeks</description>
    <arm_group_label>Mycophenolate Mofetil Monotherapy</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antibody induction</intervention_name>
    <description>According to manufacturer recommendation</description>
    <arm_group_label>Mycophenolate Mofetil Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>According to manufacturer recommendation</description>
    <arm_group_label>Mycophenolate Mofetil Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticosteroid</intervention_name>
    <description>According to manufacturer recommendation</description>
    <arm_group_label>Mycophenolate Mofetil Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, 18 to 65 years of age

          -  Patients undergoing primary kidney transplantation

        Exclusion Criteria:

          -  Recipients of multiple organ transplants

          -  Prior therapy with CellCept

          -  Presence or history of malignancies, except for successfully treated basal or squamous
             cell carcinoma of the skin

          -  Active peptic ulcer or active serious digestive system disease that may affect the
             absorption of CellCept
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Chair</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coppito</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2011</study_first_submitted>
  <study_first_submitted_qc>February 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <results_first_submitted>October 3, 2014</results_first_submitted>
  <results_first_submitted_qc>February 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2015</results_first_posted>
  <last_update_submitted>April 8, 2016</last_update_submitted>
  <last_update_submitted_qc>April 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mycophenolate Mofetil (MMF) Monotherapy</title>
          <description>Participants received an initial dose of MMF 1 gram (g), orally (PO), twice per day (BID), started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Graft loss</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>MMF Monotherapy</title>
          <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.60" spread="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Acute Rejection</title>
        <description>Diagnosis of acute rejection was suspected in any participant with an increase in serum creatinine greater than or equal to (â‰¥) 25 percent (%). All suspected acute rejections were confirmed by biopsy. The start date of acute rejection was identified as the date of biopsy.</description>
        <time_frame>Day 1, Weeks 2, 4, 12, 24, and 28</time_frame>
        <population>Intent-to-treat (ITT) population: all eligible participants who had at least baseline (BL) and 1 assessment of pharmacokinetics (PK) and pharmacodynamics (PD). Acute rejection was analyzed in any participant with an increase in serum creatinine of 25%.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Acute Rejection</title>
          <description>Diagnosis of acute rejection was suspected in any participant with an increase in serum creatinine greater than or equal to (â‰¥) 25 percent (%). All suspected acute rejections were confirmed by biopsy. The start date of acute rejection was identified as the date of biopsy.</description>
          <population>Intent-to-treat (ITT) population: all eligible participants who had at least baseline (BL) and 1 assessment of pharmacokinetics (PK) and pharmacodynamics (PD). Acute rejection was analyzed in any participant with an increase in serum creatinine of 25%.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Rejection</title>
        <description>The mean time, in days, from the date of enrollment to date of biopsy confirming acute rejection.</description>
        <time_frame>Day 1, Weeks 2, 4, 12, 24, and 28</time_frame>
        <population>ITT population; only participants with acute or biopsy-proven rejection were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Rejection</title>
          <description>The mean time, in days, from the date of enrollment to date of biopsy confirming acute rejection.</description>
          <population>ITT population; only participants with acute or biopsy-proven rejection were included in the analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.67" spread="21.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Graft Loss</title>
        <description>An allograft was presumed to be lost if a participant started dialysis and was not able to subsequently be removed from dialysis.</description>
        <time_frame>Day 1, Weeks 2, 4, 12, 24, and 28</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Graft Loss</title>
          <description>An allograft was presumed to be lost if a participant started dialysis and was not able to subsequently be removed from dialysis.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Surviving</title>
        <time_frame>Day 1, Weeks 2, 4, 12, 24, and 28</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Surviving</title>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Mycophenolate Acid (MPA) by Visit and Timepoint</title>
        <description>Drug quantification of total MPA (micrograms per milliliter [mcg/mL]) in the plasma was measured at time (T) = 0 minutes (min), 40 mins, and 120 mins.</description>
        <time_frame>Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up Visit), and any unscheduled visits</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Mycophenolate Acid (MPA) by Visit and Timepoint</title>
          <description>Drug quantification of total MPA (micrograms per milliliter [mcg/mL]) in the plasma was measured at time (T) = 0 minutes (min), 40 mins, and 120 mins.</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T=0, Week 2 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 12 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 24 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, overall mean value (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, Week 2 (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.44" spread="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.96" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, Week 12 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, Week 24 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.47" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, overall mean value (n=165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.63" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 2 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.86" spread="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.95" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 12 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.57" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.91" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 24 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.04" spread="6.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.03" spread="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, overall mean value (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.92" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free MPA (mcg/mL) by Visit</title>
        <description>Drug quantification of free MPA in the plasma was measured at T = 0, 40, and 120 mins.</description>
        <time_frame>Weeks 2, 4, 12, 24, safety follow-up (Week 28), and any unscheduled visits</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Free MPA (mcg/mL) by Visit</title>
          <description>Drug quantification of free MPA in the plasma was measured at T = 0, 40, and 120 mins.</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T=0, Week 2 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 4 (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 12 (n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 24 (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, overall mean value (n=154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, Week 2 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, Week 12 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, Week 24 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=40, overall mean value (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 2 (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 12 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 24 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, overall mean value (n=165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR)</title>
        <description>BPAR was defined according to 1997 Banff Criteria as a biopsy Banff grade of IA, IB, IIA, IIB, or III. Grade IA was defined as significant interstitial infiltration with greater than (&gt;)25% of parenchyma affected, and foci of moderate tubulitis with &gt;4 mononuclear cells per tubular cross section or group of 10 tubular cells. Grade IB was defined as significant interstitial infiltration with &gt;25% parenchyma affected, and foci of severe tubulitis with &gt;10% mononuclear cells per tubular cross section or group of 10 tubular cells. Grade IIA was defined as mild to moderate intimal arteritis. Grade IIB was defined as severe intimal arteritis comprising &gt;25% of the luminal area. Grade III was defined as transmural arteritis and/or arterial fibrinoid changes and necrosis of medial smooth muscle cells.</description>
        <time_frame>Day 1, Weeks 2, 4, 12, 24, and 28</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR)</title>
          <description>BPAR was defined according to 1997 Banff Criteria as a biopsy Banff grade of IA, IB, IIA, IIB, or III. Grade IA was defined as significant interstitial infiltration with greater than (&gt;)25% of parenchyma affected, and foci of moderate tubulitis with &gt;4 mononuclear cells per tubular cross section or group of 10 tubular cells. Grade IB was defined as significant interstitial infiltration with &gt;25% parenchyma affected, and foci of severe tubulitis with &gt;10% mononuclear cells per tubular cross section or group of 10 tubular cells. Grade IIA was defined as mild to moderate intimal arteritis. Grade IIB was defined as severe intimal arteritis comprising &gt;25% of the luminal area. Grade III was defined as transmural arteritis and/or arterial fibrinoid changes and necrosis of medial smooth muscle cells.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MPA Area Under the Concentration - Time Curve From Time 0 to 12 Hours (AUC0-12) (mcg/mL) by Visit</title>
        <description>The AUC0-12 of MPA was estimated on the validated limited sampling strategy, AUC (milligrams multiplied by height over liter [mg.h/L]) = 7.182 + 4.607 multiplied by (*) concentration at 0 minutes (C0)+ 0.998 * the concentration at 40 minutes (C0.67) + 2.149 * the concentration at 120 minutes (C2).</description>
        <time_frame>Predose and 40 minutes and 2 hours postdose at Weeks 2, 4, 12, and 24, and at the Safety follow-up (Week 28)</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>MPA Area Under the Concentration - Time Curve From Time 0 to 12 Hours (AUC0-12) (mcg/mL) by Visit</title>
          <description>The AUC0-12 of MPA was estimated on the validated limited sampling strategy, AUC (milligrams multiplied by height over liter [mg.h/L]) = 7.182 + 4.607 multiplied by (*) concentration at 0 minutes (C0)+ 0.998 * the concentration at 40 minutes (C0.67) + 2.149 * the concentration at 120 minutes (C2).</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>mcg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inosine MonoPhosphate DeHydrogenase (IMPDH) Activity by Visit and Timepoint</title>
        <description>IMPDH activity in peripheral blood mononuclear cells (PBMCs) was measured at 2 timepoints per visit, 0 and 120 minutes and presented in enzyme units. The unit of measure of enzyme activity is &quot;U&quot;. One U is defined as the amount of the enzyme that produces a certain amount of enzymatic activity that is, the amount that catalyzes the conversion of 1 micro mole of substrate per minute under pre-specified conditions (temperature, pH).</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Inosine MonoPhosphate DeHydrogenase (IMPDH) Activity by Visit and Timepoint</title>
          <description>IMPDH activity in peripheral blood mononuclear cells (PBMCs) was measured at 2 timepoints per visit, 0 and 120 minutes and presented in enzyme units. The unit of measure of enzyme activity is &quot;U&quot;. One U is defined as the amount of the enzyme that produces a certain amount of enzymatic activity that is, the amount that catalyzes the conversion of 1 micro mole of substrate per minute under pre-specified conditions (temperature, pH).</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>enzyme units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T=0, BL (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 2 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96" spread="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 12 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.74" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 24 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.58" spread="10.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, safety follow-up (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, mean value (n=204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, BL (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 2 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 12 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 24 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" spread="6.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, safety follow-up (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, mean value (n=160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IMPDH Expression I by Visit and Timepoint</title>
        <description>IMPDH I gene expression was measured by real time polymerase chain reaction (QRT-PCR) based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of messenger ribonucleic acid (mRNA) copies per cell (copies/cell).</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>IMPDH Expression I by Visit and Timepoint</title>
          <description>IMPDH I gene expression was measured by real time polymerase chain reaction (QRT-PCR) based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of messenger ribonucleic acid (mRNA) copies per cell (copies/cell).</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>number of mRNA copies/cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T=0, BL (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 2 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.29" spread="188.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 12 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="15.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 24 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11803.48" spread="20432.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, mean value (n=205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.48" spread="2473.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, BL (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 2 (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4146.17" spread="14891.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1692.11" spread="6690.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 12 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1556.06" spread="5856.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 24 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" spread="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.30" spread="179.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1038.52" spread="1781.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, mean value (n=164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1899.45" spread="8824.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IMPDH Expression II by Visit and Timepoint</title>
        <description>IMPDH II gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>IMPDH Expression II by Visit and Timepoint</title>
          <description>IMPDH II gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>number of mRNA copies/cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T=0, BL (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.33" spread="19.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 2 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.43" spread="21.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.16" spread="30.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 12 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.43" spread="24.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 24 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.21" spread="19.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.86" spread="37.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.57" spread="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, mean value (n=205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.82" spread="23.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, BL (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 2 (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.64" spread="309.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.32" spread="206.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 12 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.11" spread="82.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 24 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.00" spread="22.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.51" spread="42.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.19" spread="155.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, mean value (n=164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.71" spread="208.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 8 (IL-8) Expression by Visit and Timepoint</title>
        <description>IL-8 gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 8 (IL-8) Expression by Visit and Timepoint</title>
          <description>IL-8 gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>number of mRNA copies/cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T=0, BL (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4532.72" spread="11598.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 2 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29960.41" spread="128979.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54101.30" spread="262581.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 12 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1829.87" spread="6411.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 24 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10391.60" spread="42574.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1254.29" spread="1150.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19148.94" spread="49991.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, mean value (n=205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20748.32" spread="1333817.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, BL (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 2 (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1028.93" spread="4210.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21227.11" spread="103517.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 12 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12022.83" spread="63647.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 24 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9418.65" spread="29084.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397887.30" spread="688477.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.14" spread="457.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, mean value (n=164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17512.31" spread="110920.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Necrosis Factor (TNF) Expression by Visit and Timepoint</title>
        <description>TNF gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Necrosis Factor (TNF) Expression by Visit and Timepoint</title>
          <description>TNF gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>number of mRNA copies/cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T=0, BL (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4532.72" spread="11598.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 2 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29960.41" spread="128979.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54101.30" spread="262581.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 12 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1829.87" spread="6411.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, Week 24 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10391.60" spread="42574.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1254.29" spread="1150.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19148.94" spread="49991.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=0, mean value (n=205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20748.32" spread="133817.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, BL (n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 2 (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1028.93" spread="4210.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 4 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21227.11" spread="103517.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 12 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12022.83" spread="63647.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, Week 24 (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9418.65" spread="29084.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, safety follow-up (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397887.30" spread="688477.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, unscheduled visit (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.14" spread="457.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T=120, mean value (n=164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17512.31" spread="110920.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Infection</title>
        <description>Infections were graded according to the World Health Organization (WHO) worst grade observed.</description>
        <time_frame>BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)</time_frame>
        <population>Safety population: all enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Infection</title>
          <description>Infections were graded according to the World Health Organization (WHO) worst grade observed.</description>
          <population>Safety population: all enrolled participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acarodermatitis (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchitis (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cytomegalovirus (CMV) infection (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMV infection (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMV infection (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMV viraemia (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastroenteritis proteus (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal infection (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Legionella infection (life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral herpes (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis (life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tracheitis (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urethritis (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary tract infection (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary tract infection (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Gastrointestinal Toxicities</title>
        <description>Gastrointestinal adverse events (AEs) according to WHO worst grade observed.</description>
        <time_frame>BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-up Visit)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Gastrointestinal Toxicities</title>
          <description>Gastrointestinal adverse events (AEs) according to WHO worst grade observed.</description>
          <population>Safety population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal pain (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anal fissure (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspepsia (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastritis (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastritis erosive (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival hyperplasia (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemorrhoids (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intra-abdominal haematoma (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomatitis (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hematologic Toxicity</title>
        <description>Hematological toxicities graded according to WHO worst grade observed (Grade 1=mild, Grade 2=moderate).</description>
        <time_frame>BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hematologic Toxicity</title>
          <description>Hematological toxicities graded according to WHO worst grade observed (Grade 1=mild, Grade 2=moderate).</description>
          <population>Safety population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1 hemoglobin decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 leukocytes decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 leukocytes decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 granulocytes decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 granulocytes decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 platelets decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 bilirubin increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 bilirubin increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 alkaline phosphatase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 alkaline phosphatase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 aspartate aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 alanine aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 alanine aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 cholesterol increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 cholesterol increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 triglycerides increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 triglycerides increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 blood urea nitrogen increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 blood urea nitrogen increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spearman's Rank Correlation Coefficient Between MPA Levels and IMPDH Activity</title>
        <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Spearman's Rank Correlation Coefficient Between MPA Levels and IMPDH Activity</title>
          <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Free MPA, T=0 (n=144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA, T=120 (n=153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total MPA, T=0 (n=152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total MPA, T=120 (n=153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4505</p_value>
            <p_value_desc>Free MPA, time 0 [trough]</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Analysis of variance (ANOVA)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7322</p_value>
            <p_value_desc>Free MPA, time 120 [2 hours after administration at Week 12]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6798</p_value>
            <p_value_desc>Total MPA, time 0 [trough]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5410</p_value>
            <p_value_desc>Total MPA, time 120 [2 hours after administration at Week 12]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spearman's Rank Correlation Coefficient Between IMPDH I Expression and MPA Levels</title>
        <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
        <population>ITT population; n=number of samples analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Spearman's Rank Correlation Coefficient Between IMPDH I Expression and MPA Levels</title>
          <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
          <population>ITT population; n=number of samples analyzed</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Free MPA, T=0 (n=141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA, T=120 (n=143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total MPA, T=0 (n=147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total MPA, T=120 (n=143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3892</p_value>
            <p_value_desc>Free MPA, time 0 [trough]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6564</p_value>
            <p_value_desc>Total MPA, time 0 [trough]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7772</p_value>
            <p_value_desc>Free MPA, time 120 [2 hours after administration at Week 12]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0958</p_value>
            <p_value_desc>Total MPA, time 120 [2 hours after administration at Week 12]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spearman's Rank Correlation Coefficient Between IMPDH I Expression and Free Fraction</title>
        <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Spearman's Rank Correlation Coefficient Between IMPDH I Expression and Free Fraction</title>
          <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>p Free fraction, T=0 (n=140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p Free fraction, T=120 (n=143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5796</p_value>
            <p_value_desc>Time 0 [trough]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3428</p_value>
            <p_value_desc>Time 120 [2 hours after administration at Week 12]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spearman's Rank Correlation Coefficient Between IMPDH II Expression and MPA Levels</title>
        <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Spearman's Rank Correlation Coefficient Between IMPDH II Expression and MPA Levels</title>
          <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Free MPA, T=0 (n=145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA, T=120 (n=153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total MPA, T=0 (n=152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total MPA, T=120 (n=153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9372</p_value>
            <p_value_desc>Free MPA, time 0 [trough]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9904</p_value>
            <p_value_desc>Total MPA, time 0 [trough]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3658</p_value>
            <p_value_desc>Free MPA, time 120 [2 hours after administration at Week 12]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2987</p_value>
            <p_value_desc>Total MPA, time 120 [2 hours after administration at Week 12]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spearman's Rank Correlation Coefficient Between IMPDH II Expression and Free Fraction</title>
        <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Spearman's Rank Correlation Coefficient Between IMPDH II Expression and Free Fraction</title>
          <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>p Free fraction, T=0 (n=144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p Free fraction, T=120 (n=153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7455</p_value>
            <p_value_desc>time 0 [trough]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8504</p_value>
            <p_value_desc>Time 120 [2 hours after administration at Week 12]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spearman's Rank Correlation Coefficient Between IMPDH Inhibition and Risk of Acute Rejection</title>
        <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Spearman's Rank Correlation Coefficient Between IMPDH Inhibition and Risk of Acute Rejection</title>
          <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IMPDH I expression, T=0 (n=189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IMPDH I expression T=120 (n=145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IMPDH II expression, T=0 (n=196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IMPDH II expression (T=120, n=155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPDH Activity, T=0 (n=198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IMPDH Activity, T=120 (n=155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6847</p_value>
            <p_value_desc>IMPDH I, time 0 [trough]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3184</p_value>
            <p_value_desc>IMPDH I, time 120 [2 hours after administration at Week 12]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3862</p_value>
            <p_value_desc>IMPDH II, time 0 [trough]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9040</p_value>
            <p_value_desc>IMPDH II, time 120 [2 hours after administration at Week 12]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0907</p_value>
            <p_value_desc>IMPDH activity, time 0 [trough]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9630</p_value>
            <p_value_desc>IMPDH activity, time 120 [2 hours after administration at Week 12]</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Infection</title>
        <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
        <population>ITT population; n=number of samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Infection</title>
          <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
          <population>ITT population; n=number of samples analyzed.</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IMPDH I expression (n=334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IMPDH II expression (n=351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4130</p_value>
            <p_value_desc>IMPDH I</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3823</p_value>
            <p_value_desc>IMPDH II</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Hematologic Toxicity</title>
        <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Hematologic Toxicity</title>
          <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
          <population>ITT population</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IMPDH I expression (n=334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IMPDH II expression (n=351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0316</p_value>
            <p_value_desc>IMPDH I</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9440</p_value>
            <p_value_desc>IMPDH II</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Gastrointestinal Toxicity</title>
        <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Gastrointestinal Toxicity</title>
          <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
          <population>ITT population</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IMPDH I expression (n=334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IMPDH II expression (n=351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1328</p_value>
            <p_value_desc>IMPDH I</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5760</p_value>
            <p_value_desc>IMPDH II</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Infection</title>
        <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
        <population>ITT population; n=number of samples</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Infection</title>
          <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
          <population>ITT population; n=number of samples</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Free MPA (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total MPA (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC MPA (n=152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7332</p_value>
            <p_value_desc>Free MPA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2681</p_value>
            <p_value_desc>Total MPA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7087</p_value>
            <p_value_desc>AUC MPA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Hematologic Toxicity</title>
        <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
        <population>ITT population; n=number of samples</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Hematologic Toxicity</title>
          <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
          <population>ITT population; n=number of samples</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Free MPA (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total MPA (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC MPA (n=152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9432</p_value>
            <p_value_desc>Free MPA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5177</p_value>
            <p_value_desc>Total MPA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6398</p_value>
            <p_value_desc>AUC MPA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Gastrointestinal Toxicity</title>
        <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
        <time_frame>BL and Weeks 2, 4, 12, and 24</time_frame>
        <population>ITT population; n=number of samples</population>
        <group_list>
          <group group_id="O1">
            <title>MMF Monotherapy</title>
            <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Gastrointestinal Toxicity</title>
          <description>The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used.</description>
          <population>ITT population; n=number of samples</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Free MPA (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total MPA (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC MPA (n=152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0656</p_value>
            <p_value_desc>Free MPA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0131</p_value>
            <p_value_desc>Total MPA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0515</p_value>
            <p_value_desc>AUC MPA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were recorded throughout treatment to the safety evaluation follow up 4 weeks after treatment discontinuation, for up to 28 weeks.</time_frame>
      <desc>The safety assessment population included all eligible participants who received at least 1 dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>MMF Monotherapy</title>
          <description>Participants received an initial dose of MMF 1 g, PO, BID, started within 5 days of transplant, for up to 24 weeks. MMF dose could be titrated to a maximum daily dose of 2 g (minimum daily dose was 1 g). Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>WHO Guidelines</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema of the left leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CMV infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection due to Legionella and Pseudomonas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Proteus mirabilis infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acute rejection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Acute vascular and interstitial rejection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increase in creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostatic adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Carcinoma of the bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tubulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Ureteral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urinary anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Acute tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>WHO Guidelines</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Antithrombin III deficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lymphocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gingival hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lipidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post-procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyperlipemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

